Evidence map›Paper›PMID 29352662›Full record

ArticleMolecular genetics and metabolism2018

Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study.

Igor Nestrasil, Alia Ahmed, Josephine M Utz, Kyle Rudser, Chester B Whitley, Jeanine R Jarnes-Utz

2 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Molecular genetics and metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00668187 recruitingnot on this map

A Natural History Study of the Gangliosidoses

TypeobservationalSponsorUniversity of MinnesotaRan2010 to 2027Enrolled52ConditionsTay-Sachs Disease, Sandhoff Disease, Late Onset Tay-Sachs Disease, GM1 Gangliosidosis
NCT02030015 phase4terminatednot on this map

Synergistic Enteral Regimen for Treatment of the Gangliosidoses (Syner-G)

TypeinterventionalSponsorUniversity of MinnesotaRan2015 to 2019Enrolled16ConditionsGM1 Gangliosidoses, GM2 Gangliosidoses, Tay-Sachs Disease, Sandhoff DiseaseArmsmiglustat, Ketogenic Diet
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. GM1 gangliosidosis type II: Results of a 10-year prospective study.Genetics in medicine : official journal of the American College of Medical Genetics · 2024
    Observational
  12. Review
  13. Article
  14. GM1 Gangliosidosis Type II: Results of a 10-Year Prospective Study.medRxiv : the preprint server for health sciences · 2024
    Article
  15. Review
  16. Article
  17. Article
  18. Zebra-Sphinx: Modeling Sphingolipidoses in Zebrafish.International journal of molecular sciences · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Igor NestrasilDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Alia AhmedDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Josephine M UtzDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Kyle RudserDivision of Biostatistics, University of Minnesota, Minneapolis, MN, USA.
Chester B WhitleyDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA; Advanced Therapies Department, University of Minnesota, Fairview, Minneapolis, MN, USA; Gene Therapy Center, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA; Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA.
Jeanine R Jarnes-UtzDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA; Advanced Therapies Department, University of Minnesota, Fairview, Minneapolis, MN, USA; Gene Therapy Center, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA; Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA. Electronic address: utzx0002@umn.edu.
University of Minnesota · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Training & EducationU54NS065768 · NINDS · UNIVERSITY OF MINNESOTA · PI WHITLEY, CHESTER B. · 2009 to 2024
$17.7M
NCATS NIH HHS UL1 TR002494NINDS NIH HHS U54 NS065768
6 · The paper itself

Abstract

backgroundGM1-gangliosidosis and GM2-gangliosidosis (Tay-Sachs disease and Sandhoff disease) are unrelenting heritable neurodegenerative conditions of lysosomal ganglioside accumulation. Although progressive brain atrophy is characteristic, longitudinal quantification of specific brain structures has not been systematically studied.

objectivesThe goal of this longitudinal study has been to quantify and track brain MRI volume changes, including specific structure volume changes, at different times in disease progression of childhood gangliosidoses, and to explore quantitative brain MRI volumetry (qMRI) as a non-invasive marker of disease progression for future treatment trials.

methodsBrain qMRI studies were performed in 14 patients with gangliosidoses (9 infantile, 5 juvenile) yearly. Cerebellar cortex and white matter, caudate, putamen, corpus callosum, ventricles, total brain, and intracranial volumes were measured, as well as total brain volume. Age-matched controls were available for the patients with the juvenile phenotype.

resultsThe infantile phenotype of all gangliosidoses showed a consistent pattern of macrocephaly and rapidly increasing intracranial MRI volume with both (a) brain tissue volume (cerebral cortex and other smaller structures) and (b) ventricular volume (P<0.01 for all). In contrast to apparent enlargement of the total brain volume, and chiefly the enlarged cerebral cortex, a subset of smaller brain substructures generally decreased in size: the corpus callosum, caudate and putamen became smaller with time. The volume of cerebellar cortex also decreased in patients with infantile GM1-gangliosidosis and juvenile GM1- and GM2-gangliosidosis; however, infantile GM2-gangliosidosis cerebellar cortex was the exception, increasing in size. Elevated intracranial pressure (estimated by lumbar spinal pressure) was a common finding in infantile disease and showed continued increases as the disease progressed, yet lacked MRI signs of hydrocephalus except for increasing ventricular size. Notably, in patients with juvenile gangliosidosis, macrocephaly and elevated intracranial pressure were absent and total brain volume decreased with time compared to controls (P=0.004).

conclusionsThe disease course of infantile versus juvenile gangliosidoses is clearly distinguished by the rate of brain disease progression as characterized by qMRI. Assessments by qMRI represent a robust non-invasive method for monitoring CNS changes in the clinical course of gangliosidoses and is ideally suited to monitor effects of novel CNS-directed therapies in future clinical trials.

Indexed as

ChildChild, PreschoolDisease ProgressionFemaleGangliosidesGangliosidoses, GM2Gangliosidosis, GM1HumansInfantLongitudinal StudiesMagnetic Resonance ImagingMaleGangliosidesGangliosidosisGM1-gangliosidosisGM2-gangliosidosisSandhoff diseaseTay-Sachs diseaseβ-galactosidase

Identifiers

PMID29352662
PMCPMC5832355
OpenAlexW2781230909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.